semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Diabetes Hyperglycemia Documented + HIV ELISA. Diabetes mellitus (DM) will be defined as: Documented diagnosis of type 2 diabetes mellitus or FPG greater than or equal to 126 mg/dl on two occasions or casual blood glucose greater than or equal to 200 mg/dL and symptoms of diabetes. Impaired Fasting Glucose (IFG) defined as: FPG greater than or equal to 100 mg/dl and less than 126 mg/dl on one or more occasions within past year. Age 18+, male or female  Type 1 Diabetes. Known current pregnancy or pregnancy within 6 mo. Documented hemoglobinopathy. Changes in antiretroviral therapy within 3 months. History of anemia (Hb less than 9g/dL in past 6 months). Active opportunistic Infection or opportunistic Infection within 3 mo. Creatine greater than 1.8 mg/dL or known end stage renal disease (ESRD). Changes in diabetes therapies within 3 mo (excluding dose adjustments). Subject is deemed unable to comply with requirements of study participation. Use of oral corticosteroid within the past 3 mo (stable dose inhaled steroids will be allowed). Blood transfusion within 3 months
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Polycystic Ovary Syndrome Irregular menses or anovulaty cycles High free testosterone > 0.035 nmol/l or hirsutism PCO in vaginal US 1 and 2 OR 2 and 3  Age > 18 years Postmenopausal Diagnosis diabetes mellitus Use of medicine known to affect hormones measured in the project Pregnancy or planned pregnancy during study period Non-Caucasian Previous tromboembolic disease Heavy smoker > 35 years and BMI > 35 kg/m2
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Hepatocellular Carcinoma Histologically proven hepatocellular carcinoma. 2. HCC underwent curative resection within 6 weeks before registration. 3. Grossly, the resection margin should be > 1 cm. 4. Tumors, either single, < 5 cm in size or no more than 3 for size < 3 cm. 5. Patients must have a performance status of ECOG score < 2. 6. Patients must have adequate liver reservation and adequate hemogram Pugh-Child's Score < 7 The serum total bilirubin level are < 2 mg/dl The prothrombin times are < 3 sec above normal control The platelet are > 7.5 x 104 / mm3 The WBC are > 3,000 / mm3. 7. Patient must have serum creatinine < 1.5 mg/dl 8. Cardiac function with NYHA classification < Grade II 9. HBsAg (+) . 10. Signed informed consent  Patients who have non-curative resection are not eligible. 2. Resected HCCs with histologically positive margins are not eligible. 3. HCCs with radiological evidence of portal vein thrombus are not eligible. 4. Patients with other systemic diseases which required concurrent usage of glucoticosteroid or immunosuppressant agent(s) are not eligible. 5. Patients with advanced second primary malignancy are not eligible. 6. Patients with pregnancy or breast-feeding are not eligible. 7. Patients with severe cardiopulmonary diseases are not eligible. 8. Patients with clinically significant psychiatric disorder are not eligible. 9. Patients who had antineoplastic chemotherapeutic or immuno-therapeutic drugs or corticosteroids within 6 weeks of commencing the protocol are not eligible. 10. Patients who had prior lamividine and/or adefovir dipivoxil therapy are not eligible. 11. Anti-HCV positive patients are not eligible
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Cancer (All questions must be answered YES) Has the patient given written informed consent? Is the patient at least 18 years old? Does the patient have transitional cell carcinoma of the bladder with clinically apparent stage Ta, grade G1-G2? If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception? If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 14 days? Is the patient willing and able to abide by the protocol?  (All questions must be answered NO) Does the patient have more than 4 bladder tumors? Does any single bladder tumor exceed 3.5 cm in diameter? Does the patient have a single, primary (no previous diagnosis of TCC) bladder tumor <0.5 cm? Has the patient ever received Apaziquone? Does the patient have, or has the patient ever had, any bladder tumor known to be other than stage Ta or grade G1 or G2 (low grade [WHO/ISUP classification])? Does the patient have, or has the patient ever had any bladder tumor with histology other than transitional cell carcinoma? Does the patient have, or has the patient ever had, carcinoma in situ (CIS)? Does the patient have an active urinary tract infection? Does the patient have a bleeding disorder or a screening platelet count < 100 x 10^9/L?
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Patients: In order to be included in this study, patients with lung cancer must meet at 2 steps: (1) initial screening and written consent to be contacted by telephone, and (2) provision of verbal consent at the time of telephone contact to complete the survey. Step 1a: In order to be approached about the study, patients must be (1) at least 18 years of age, (2) diagnosed with lung cancer at any stage (Stages Ia-IV), (3) approved for contact by their oncologist, and (4) identified by the recruiter or identified in medical records as Black. Step 1b: In order to provide consent for contact for the telephone survey, patients must self-identify as AA/Black and must have been born in the U.S. Also, patients must be willing to give permission to contact at least one family member or friend considered as close as family who is a current cigarette smoker between the ages of 18 and 55 in order to provide consent. Step 2: At the point of the patient survey, all patients will be asked their race/ethnicity. All patients who self-identify as AA/Black as defined by this research will be administered the patient survey. Family: Family members must self-identify as AA and be between the ages of 18 and 55 to be eligible for the study. Family also must meet the following to be classified as either a current smoker (defined below) or a never smoker (defined below). These for current smoker and never smoker are based on standard used in smoking research. Current Smoker: to be included as a smoker , the family member must report having smoked at least 100 cigarettes in their lifetime, and smoked 7 or more cigarettes in the past 7 days at the time of the family member survey. Never Smokers: to be included as a never smoker , a family member must report no to having smoked at least 100 cigarettes in their lifetime  Former smokers (i.e., family who have smoked at least 100 cigarettes in their lifetime but smoked fewer than 7 cigarettes in the past 7 days) because previous research shows consistently that these individuals hold attitudes and beliefs more similar to those of current smokers than never smokers. Patients who describe themselves as AA or Black but were not born in the U.S. will be excluded from participation
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anemia Chronic Renal Insufficiency Subjects with chronic kidney disease defined as serum creatinine of 1.5 to 6.0 mg/dL for women and 2.0 to 6.0 mg/dL for men glomerular filtration rate (GFR) within 15-60 mL/min Subjects on darbepoetin alfa for 3 months or more and with a stable entry hemoglobin level of 12 (plus or minus 1 g/dL range 11-13 g/dL) Subjects receiving darbepoetin alfa on an every two, three, or four week dosing schedule female subjects with a reproductive potential must have a negative ruine pregnancy test within 7days of the first dose of study drug  No uncontrolled high blood pressure as assessed by the primary physician No known hypersensitivity to mammalian cell-derived products No known hypersensitivity to human albumin Not receiving dialysis or scheduled to receive dialysis during the course of the study No severe congestive heart failure (New York Heart Association Class IV) No known severe stable or unstable coronary artery disease
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Hepatitis C Healthy, hepatitis C virus (HCV) negative 45 year old healthy adults. Insufficient data are available in adults to judge risk in children In good general health as determined by medical history, physical examination and the following screening labs Complete Blood Count (CBC): Total WBC (White Blood Cell): 3.5-14 thousand/microliter (MCL); Hemoglobin (Hgb): Men: 12.2-18 g/dl and Women: 10.5-17 g/dl Creatinine: Men: less than or equal to 1.4 mg/dl; Women: less than or equal to 1.2 mg/dl Glucose: 50 mg/dl to less than or equal to 109 mg/dl Alanine Aminotransferase (ALT): Men 2-60 units/litre (U/I): Women: 3-40 U/I Aspartate Aminotransferase (AST): Men: 2-50 U/I, Women 2-35 U/I Total bilirubin: Men: less than or equal to 1.5 mg/dl: Women: less than or equal to 1.3 mg/dl Urinalysis: negative or trace protein, negative glucose, less than or equal to 3 Red Blood Cells (RBC)/High Power Field (HPF) and less than or equal to 5WBC/HPF (in nonmenstruating females)  Diabetes Cancer other than squamous cell skin cancer which has been excised History of myocardial infarction or arrhythmia requiring hospitalization Syncope requiring hospitalization Unconsciousness other than a simple concussion Seizures other than febrile seizures as a child <5 years of age Current liver disease (not including Gilbert's disease) Autoimmune disease (does not thyroid disease or vitiligo) Splenectomy Uncontrolled hypertension [blood pressure (BP) >150/90; anti-hypertensive medications are acceptable)
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Generalized Myasthenia Gravis Patients diagnosed as generalized myasthenia gravis Patients who are not controlled by current therapy and need plasmapheresis therapy Patients who have the high-dose steroid therapy for over a month in past years, and also who take steroid or immunosuppressant on the day of consent Patients who had not any dose increase or new dosing of steroid or immunosuppressant within 4 weeks prior to enrollment  Patients who received steroid pulse therapy, globulin therapy or plasmapheresis therapy within 12 weeks prior to enrollment Patients who had undergone thymectomy within 24 weeks prior to enrollment Patients with 3 points item in bulbar symptom of MG-ADL scale Patients with severe hepatic disorder, severe renal disorder or severe heat disorder Patients who have received treatment of malignant tumors Patients who have the anamnesis of shock or hypersensitivity to this drug Patients who have been diagnosed as hereditary fructose intolerance Patients who have the anamnesis of cerebral infarction or symptom of these diseases Patients who have been diagnosed as IgA deficiency in their past history Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections HIV-1 infected subjects 18 years of age or older Receiving HAART for at least two years At least a viral load determination per year since HAART initiation, all undetectable Patient's status is Immunological Non Responder (InR), that is, his or her viral load is reduced, but CD4+ cell count has not raised accordingly Current viral load: undetectable Patient agrees and signs informed consent  Concomitant active infectious or neoplastic disease History of new AIDS-defining events during HAART Pregnancy or breast-feeding Patients who have been subjects of an investigational agent, chemotherapy or radiotherapy within the previous 28 days Subjects requiring treatment for Tuberculosis Subjects unable to follow, or comply with the protocol interventions Subjects receiving immunosuppressive treatment, including corticosteroids
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Kidney Disease Muscle Weakness Pain Fractures, Bone Age ³ 18 CKD on hemodialysis Men and women Hemoglobin ³ 9g/dl, albumin ³ 3.0g/dl No recent (in the last three months) admissions to the hospital Ability to walk ten feet with or without a walking aid  Subjects who are pregnant or lactating Subjects with history of kidney stones Malabsorption syndromes Tertiary hyperparathyroidism defined by a parathyroid hormone of >500pg/ml, current use of corticosteroids Non-ambulatory subjects (for example paraplegic subjects) Serious fracture in the last three months, and Corrected calcium levels of 10.5 mg/dl or greater
Patient description: The patient is a 35-year-old woman with myasthenia gravis, class IIa. She complains of diplopia and fatigue and weakness that affects mainly her upper limbs. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She takes pyridostigmine 60 mg three times a day. But she still has some symptoms that interfere with her job. She is a research coordinator and has 3 children. Her 70-year-old father has hypertension. She does not smoke or use illicit drugs. She drinks alcohol occasionally at social events. Her physical exam and lab studies were not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Prostatic Hyperplasia Healthy subjects defined as individuals who are free from clinically significant illness or disease as determined by the investigator based on their medical history, physical examination, laboratory studies, ECGs, and other tests Males who are 18 years of age, inclusive Weight range 55 kg (inclusive) and body mass index 19 kg/m2 (inclusive) Willing and able to give written informed consent, willing to participate for the full duration of the study, and able to understand and follow instructions related to study procedures  Slow metabolizer for CYP2D6 as determined by screening PGx analysis History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal reactions or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer, such as St. John's Wort) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety Chronic hepatitis B and C, as evidence by positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody Positive HIV test at screening History of sensitivity to heparin or heparin-induced thrombocytopenia History of regular alcohol consumption exceeding 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening. Subjects must be able and willing to abstain from beverages and foods containing alcohol 24 hours prior to and during the dosing day A positive urine drug or alcohol (Breath test or urine) screen result at screening or check-in The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication or anytime during the study period Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period